These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Combined chemotherapy and irradiation for transitional cell cancer of the bladder: a review. Beuzeboc P; Pontvert D; Pouillart P; Cosset JM J Infus Chemother; 1995; 5(4):218-20. PubMed ID: 8934733 [No Abstract] [Full Text] [Related]
4. [Neoadjuvant chemotherapy: meta-analysis and interpretation of results in bladder cancer]. Pollera CF Suppl Tumori; 2004; 3(4):S59-61. PubMed ID: 15206215 [No Abstract] [Full Text] [Related]
5. Neoadjuvant chemotherapy for bladder transitional cell carcinoma: a new standard of care? Mazhar D; Ali N; Ngan S Future Oncol; 2007 Feb; 3(1):5-8. PubMed ID: 17280495 [No Abstract] [Full Text] [Related]
6. Neoadjuvant therapy of carcinoma of the bladder. deVere White RW Semin Urol; 1990 Aug; 8(3):197-200. PubMed ID: 2204981 [No Abstract] [Full Text] [Related]
7. Randomized trial of hexamethylmelamine versus 5-FU, doxorubicin, and cyclophosphamide (FAC) in advanced transitional cell bladder carcinoma: a Southwest Oncology Group study. Gagliano RG; Stephens RL; Costanzi JJ; Oishi N; Stuckey WJ; Grozea PN; Frank J; Crawford ED Cancer Treat Rep; 1984; 68(7-8):1025-6. PubMed ID: 6430559 [No Abstract] [Full Text] [Related]